Serum Magnesium Is The Most Frequently Used Laboratory Test For Evaluating Clinical Magnesium Status. Hypomagnesemia Has Been Associated With Many Chronic Diseases, But Currently No Consensus For A Normal Magnesemia Range Exists, Nationally Or Internationally. In Addition, Reports As Early As 1983 Showed That Means Of Serum Mg Are Similar In Both Hospitalized And Healthy Subjects, But The Variance Of Those Hospitalized Is Wider Than The Healthy Group. A Low Serum Magnesium Is A Definite Sign Of Magnesium Deficiency; However, Values Within The Reference Range Do Not Rule Out Deficiencies. A Recent Review And Many Hospital Laboratories And Researchers Use Symptomatic Hypomagnesemia To Define The Lower Range Marking Hypomagnesemia, But There Is A Large Range Of Serum Mg Above These Values Which Are Asymptomatic And Yet Do Not Denote A Fully “healthy” Magnesium Status. Two Independent Groups Have Recently Designated 0.85 – 0.95 Mmol/L As A Reliable Serum Mg Reference Range, But Only The Lower Boundary Marker, I.e. 0.85 Mmol/L Is Evidence Based. A Reliable, Evidence-based Upper Limit Of A Health Serum Mg Has Yet To Be Ascertained, And It Is Possible That Serum Mg Alone May Not Be Adequate To Designate A Compromised Magnesium Status That Is Asymptomatic Yet Portending Future Development Of Chronic Disease. According To The Current Data, An Increase In The Lower Limit Value For Serum Magnesium To 0.85 Mmol/L (2.1 Mg/dL) Is Required From A Health Point Of View. The Best Way To Diagnose A Magnesium Deficiency Is Based On The Clinical Symptoms And The Presence Of Risk Factors (anamnesis) In Combination With The Serum Magnesium.
O. Mickeis Head Of The Department Of Radiotherapy And Radiation Oncology, And Clinical Director Of The Franziskus Hospital Bielefeld, Germany, Teaching Hospital Of The Hannover Medical School (MHH). He Is The Associate Editor Of “Trace Elements And Electrolytes”- Official Organ Of The – "Society Of Magnesium Research", Germany, And – German Working Group “Trace Elements And Electrolytes In Radiation Oncology” AKTE, Germany. He Is President Of The German Magnesium Society And Chairman Of The German Working Group “Trace Elements And Electrolytes In Radiation Oncology” AKTE. One Main Focus Of His Scientific Interest Is Complementary And Alternative Medicine, Micronutrients, Traditional Medicine, And Trace Elements And Electrolytes. He Authored More Than250 Publications In Peer Reviewed National And International Scientific Journalsand Has Been Invited As Speaker At National And International Meetings.
Listen to this article
POCUS Is A Critical Diagnostic Tool In The Acute Care Setting, Allowing Clinicians To Rapidly Assess Cardiac Function In The Context Of The Patient's Clinical Condition. POCUS Performed By Anaesthesiologists Significantly Impact The Clinical Management Of Patients Scheduled For Noncardiac Surgery. Clinical Findings Were Confirmed By Follow-up Formal Transthoracic >90% Of The Time And No Severe Aortic Stenosis, Severe Ventricular Dysfunction, Or Significant Pericardial Effusion Were Missed. In The Perioperative Period, POCUS Allows For The Anaesthesiologist As A Perioperative Physician To Check For Coexisting Diagnosis, Categorize Shock, Respiratory Failure, And Ongoing Effects Of Therapeutic Treatments. Real Time Physiologic Data Reflect Dynamic Changes In Response To Medical Therapies And Follow The Evolution Of Critical Illness By Serial Examinations, Allowing For The Integration Of POCUS Findings Into A Complete Management Plan. This Brief Report Aims To Identify The Indications, Clinical Impact On Management Decisions, Andperioperative Focused Cardiac Ultrasound Accuracy In Patients Scheduled For Non-cardiac Surgery.
Anahita Dabo-Trubelja Is Clinical Member In The Department Of Anaesthesiology And Critical Care At Memorial Sloan Kettering Cancer Center In NYC. She Serves As Director Of Onco-Anesthesia Fellowship Program And Director Of POCUS, A Program She Initiated. Her Interest Focuses On Promoting Onco-Anaesthesiology As A Subspecialty And Integrating POCUS Into Daily Practice To Guide Management In The Perioperative Period.
Listen to this article
Introduction: Extracranial Internal Carotid Artery (ICA) Pseudoaneurysmsin Children, Although Uncommon, Are Life-threatening. Covered Stents Are A Good Alternative Treatment, As They Avoid The Risk Of Open Surgery And Preserve The Internal Carotid Artery.Long- Term Outcomes Were Unknown Until Recently. Report: In August 2008, A 3-years-old Child Was Treated With A Covered Stent For A Pseudoaneurysm In The Extracranial ICA. A Long-term Follow Up Is Presented. Results: The Child Was Discharged With Full Recovery And Without Neurological Sequelae. He Has Been Followed-up And Has Remained Asymptomatic For 12 Years, With CTA- Confirmed Internal Carotid Artery Patency, Without Deformation Or Evidence Of Significant Re- Stenosis. Conclusion: This The First Report Of The Long-term Outcome Of A Covered Stent In A Child Treated At 3 Years Of Age, With A 12-year Follow-up. The Good Performance Of The Covered Stent In This Case Reinforces Its Adoption As A First-line Option In The Treatment Of Extracranial ICA Pseudoaneurysms Inchildren.
• Prof. Roberto Sánchez, MD Professor Of Surgery • Faculty Of Medicine- University Of Concepción- CHILE Fellow Of The American College Of Surgeons • Ancien Resident Etranger Des Hopitaux De Paris • MembreAsocieeEtrangerSociété De ChirurgieVasculaire Et Endovasculaire De Langue Francaise (SCVE) • Non-european Membership European Society Of Vascular And Endovascular Surgery (ESVS)
Listen to this article